Trial Profile

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Masitinib (Primary) ; Donepezil; Galantamine; Memantine; Rivastigmine
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Sponsors AB Science

Most Recent Events

23 Jun 2025 Results presented in the AB Science Media Release.
30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
29 Jul 2021 According to an AB Science media release, the full abstract will be published in a supplement of Alzheimer's & Dementia (the journal of the Alzheimer's Association).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com